Personal Genome Diagnostics Inc. (PGDx), a leading provider of advanced cancer genome testing products and services, today announced that it has licensed rights to patent pending microsatellite instability (MSI) testing technology from Johns Hopkins University to help identify candidates for immune checkpoint inhibition. PGDx already includes the MSI technology in its pan cancer genomic tissue assays for patients and drug developers, and will be incorporating it into the recently launched PlasmaSELECT™ 64 non-invasive pan cancer assay. The company also includes the MSI technology in its PROGENEUS™ technology transfer enterprise solution, which enables advanced cancer genomic testing by local and regional laboratories that have next-generation sequencing (NGS) capabilities.